Orantinib

{
  "id": "MLC-T-ONC-006138",
  "term": "Orantinib",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A substance being studied in the treatment of cancer. Orantinib blocks proteins involved in the growth and spread of cancer cells. It may also prevent the growth of new blood vessels that tumors need to grow. It is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Also called SU006668 and SU6668.",
    "An orally bioavailable receptor tyrosine kinase inhibitor. Orantinib binds to and inhibits the autophosphorylation of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR), thereby inhibiting angiogenesis and cell proliferation. Orantinib also inhibits the phosphorylation of the stem cell factor receptor tyrosine kinase c-kit, often expressed in acute myelogenous leukemia cells."
  ],
  "synonyms": [
    "SU006668",
    "SU6668"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/orantinib/"
}